Stopping GLP-1s: Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, and Rybelsus Compared

Every GLP-1 medication, whether it is Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, or Rybelsus, works the same way and rebounds the same way when you stop: appetite-suppressing hormone signaling fades, hunger and food noise return, and the body works to defend the weight it lost. What differs by drug is how fast that fade happens and roughly how much weight tends to come back. This guide compares all six side by side, then points you to the deep-dive for your specific medication.

How fast each drug clears your system

Clearance time depends entirely on the molecule's half-life, not the brand name. Ozempic, Wegovy, and Rybelsus all share the same active ingredient (semaglutide), so they clear on the same schedule; Zepbound and Mounjaro share tirzepatide; Saxenda uses the much shorter-acting liraglutide.

Saxenda's much shorter half-life is why it needs daily dosing instead of weekly, and it means the appetite rebound after stopping arrives on a compressed timeline, days instead of weeks. See our detailed timelines for Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, and Rybelsus.

How much weight tends to come back, by drug

Regain data comes from different trials with different designs, so treat these as directional, not a precise head-to-head. The consistent pattern: drugs that produce larger losses on treatment tend to show larger absolute regain off treatment, because there is more to give back.

Across every drug in the class, roughly 60 to 75 percent of lost weight tends to return within about a year without a maintenance plan, with the steepest climb in the first 3 to 6 months. This is physiology, not failure, appetite hormones like ghrelin rebound, and metabolic rate stays lowered from the weight already lost, so the body has both more hunger and a lower calorie ceiling working against it at the same time.

What does not change, no matter which drug you were on

• None of them cause chemical dependence. There is no dangerous withdrawal syndrome with any GLP-1 medication; what people call "withdrawal" is the return of appetite signaling.
• The decision to stop, taper, or switch is always a clinician decision. No drug in this class should be started, stopped, or adjusted on your own.
• The same four pillars protect your loss. Protein, strength training, sleep, and daily movement blunt the rebound regardless of which molecule you were on.
• The first 3 to 6 months are the highest-risk window. Faster-clearing drugs (Saxenda) compress that risk into a shorter runway; slower-clearing drugs (semaglutide, tirzepatide) give you more lead time to prepare.

Questions worth bringing to your clinician

Whatever drug you are on, the conversation with your prescriber is the same shape. Our tapering guide and taper planner can help you organize your thinking before that appointment, they are informational scaffolds to bring to a clinician, never a prescription.

• Is a gradual taper, a reduced-frequency schedule, or an abrupt stop more appropriate for me?
• What should I watch for in the weeks my specific drug is clearing?
• If I am on a drug for diabetes (Mounjaro, or diabetes-dosed Rybelsus), how will we monitor blood sugar after stopping?
• What does a realistic maintenance plan look like for my situation?

The bottom line

Every GLP-1 medication rebounds the same way when you stop, appetite comes back as the drug clears, and weight tends to follow unless a maintenance plan is in place, but the speed of that clearance and the scale of the regain both depend on the specific drug and dose. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Zepbound, Mounjaro) clear over several weeks; liraglutide (Saxenda) clears in days. Larger on-treatment losses tend to mean larger absolute regain off treatment. Whichever drug you are stopping, the plan that protects your progress is the same: protein, strength training, sleep, movement, and a clinician in the loop.